Enfermedad de parkinson: tratamiento con levodopa y otras alternativas (página 2)

Hornykiewicz OD. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future. Neurology 1970; 20: 1-5

Hyman S, Chisholm D, Kessler R, Patel V, Whiteford HA.Mental disorders in disease control priorities in developing countries. In Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, eds. Disease control priorities in developing countries. Washington DC: World Bank; 2006. p. 605-25.

Janus C., Pearson J., McLaurin J.A., Mathews P.M., Juang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T.J., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. Aß peptide immunization reduces behavioural impair -ment and plaques in a model of Alzheimer"s disease. Nature, 2000; 408:979-982.

Jellinger KA. Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 2011; 310: 107-11.

Juncos JL. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Neurol Clin 1992; 10: 487-509.

Juri CC, Chaná PC. Levodopa en la Enfermedad de Parkinson. ¿qué hemos aprendido? Rev Méd Chile 2006; 134: 893-901

Leentjens AF, Marinus J, Van Hilten JJ, Lousberg R, Verhey FR. The contribution of somatic symptoms to the diagnosisof depressive disorder in Parkinson"s disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003; 15: 74-7.

Lucking CB, Durr A, Bonifati V. Association between early-onset Parkinson´s disease and mutations in the parquin gene. French Parkinson´s Disease Genetics Study group. N Engl J Med 2000; 342: 1560-1567.

Luquin, M. R., García-ruiz, P. J., Martí, M. J., Rojo, A., Vela, L., Grandas, F. J., Santos-garcía, D. (2012). Levodopa en el tratamiento de la enfermedad de Parkinson?: mitos y realidades, 55(11), 669–688.

Malaspina D, Corcoran C, Schobel S, Hamilton SP. Epidemiological and genetic aspects of neuropsychiatric disorders. En: Yudofsky SC, Hales RE (eds). The American psychiatric publishing textbook of neuropsychiatry and behavioral sciences. Quinta edición. Arlington: APPI; 2008.

Marsh L, Margolis RL. Neuropsychiatric aspects of movement disorders. En: Kaplan, Sadock"s (eds.). Comprehensive textbook of psychiatry. Philadelphia: Lippincott Willimas & Wilkins; 2009; pp.481-493.

Mercuri N. B., Bernardi G. The "magic" of L-dopa: why is it the gold standard Parkinson"s disease therapy? Trends Pharmacol Sci 2005; 26: 341-4.

Mizutani Y, Okada Y, Ogawa M, Hasegawa T, Nabeshima T. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients. Biol Pharm Bull 1995; 18: 1729-37. 

National Collaborating Centre for Chronic Conditions. Parkinson"s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006.

Obeso JA, Rodríguez-Oroz MC, Zamarbide I. Capítulo 6: Enfermedad de Parkinson. Perspectivas. En: Segovia JM, Mora F, Enfermedades neurodegenerativas. Madrid, Farmaindustria, 2002. p. 71-83

Organización mundial de la salud. Informe sobre la situación mundial de las enfermedades no transmisibles 2010. Resumen de orientación. Ginebra, Suiza 2010.

Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson"s disease. Brain 2008; 131: 642-50.

Parkinson, J., & Parkinson, D. E. L. A. E. D. E. (1871). Capitulo 5 farmacología de las drogas antiparkinsonianas, 59–73.

Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002;14:223-236.

Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson"s disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133: 3434-43

Pfeiffer RF. Gastrointestinal dysfunction in Parkinson"s disease.Lancet Neurol 2003; 2: 107-16.

Poewe W. Clinical measures of progression in Parkinson"s disease. Mov Disord 2009; 24 (Suppl 2): S671-6.

Pollock M, Hornabrook RW. The prevalence, natural history and dementia of Parkinson"s disease. Brain 1966; 89: 429-48.

Pradilla A, Vesga A, León S, y grupo GENECO. Estudio neuroepidemiológico nacional

(EPINEURO) colombiano. Rev Panam Salud Publica/Pan Am J Public Health 14(2), 2003.

Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson"s disease. Mov Disord 2008; 23: 183-9; quiz 313.

Sandoval LI, Jiménez F, Soto J et al. Resultados del tratamiento quirúrgico de la enfermedad de Parkinson en la Unidad de Neurocirugía Funcional, Estereotaxia y Radiocirugía, del Hospital General de México en el período de 1992 a 2009. Rev Mex Neuroci 2010;11(1):20-25.

Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson"s disease. Mov Disord 2003; 18: 1459-63.

Una, D., En, E., Siglo, E. L., & Díaz, R. S. (2004). Otras demencias neurodegenerativas, LXVII, 10–12.

Valldeoriola F, Iranzo de Riquer A. Trastornos del sueño y fatiga en la enfermedad de Parkinson. En Martinez-Martin P, Sanchez-Andres JV, eds. Trastornos no motores en la enfermedad de Parkinson. Barcelona: Viguera; 2009. p. 189-207.

Virues-Ortega J, Rodriguez-Blazquez C, Micheli F, Carod-Artal FJ, Serrano-Duenas M, Martinez-Martin P. Cross-cultural evaluation of the modified Parkinson Psychosis Rating Scale across disease stages. Mov Disord 2010; 25: 1391-8.

Waters CH. Complications of Parkinson´s disease and its therapy. En Diagnosis and Management of Parkinson´s disease. Ed. Cheryl C Waters.. 2002; 135-165.

Weaver FM, Follet K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301 (1):63-73.

Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986; 36: 739-44.

Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimization in the treatment of Parkinson's disease. Clin Pharmacokinet 1996; 30: 463

Autor:

Arévalo R, L. F.1

1Facultad de Ciencias, Programa de Biología, Universidad del Tolima. Tolima, Colombia.